Editor, Nanotechnology for Drug Delivery
Research Category OWNER:
Nanotechnology for Drug Delivery – Investigator Initiated New Research Category
Expert, Author, Writer:
- CANCER BIOLOGY & Innovations in Cancer Therapy
- Cell Biology, Signaling & Cell Circuits
Tilda Barliya, PhD
Specialties: Oncology, Cell biology, Ophthalmology and Nanotechnology.
I am a research scientist at the Department of Ophthalmology at the Rabin Medical Center.
- I am a highly skilled cancer cell biologist with strong background and interest in nanotechnology for drug delivery. I completed my first Post-doctoral fellowship at Weill Cornell Medical Center in NYU exploring the preventative effects of different chemotherapeutic drugs on breast cancer progression. Thereafter I conducted a second post-doc at UNC in field of nanotechnology exploring new drug delivery platforms and performed as an active editor and author in several scientific blogs. Few years ago, I joined the ophthalmology research team at the Rabin Medical Center exploring new application of nanotechnology in eye diseases as well as understanding the underlying cause of different retinal diseases.
- I bring a wide-spectrum of expertise in multidisciplinary field of nanotechnology oncology as well as ophthalmology.
Professional in the fields of biotechnology, nanotechnology and medical devices. PhD in tumor and vascular biology from Sackler School of Medicine, Tel-Aviv University, with 10 years of experience in Cancer research. Explored and developed the antiangiogenic properties of Hypericin. Drug entered Phase I clinical trials for the treatment of brain tumors.
Expertise in the following fields:
- Tumor cell biology (In vivo and In vitro: WB, IF, ELISA, IP, RT-PCR,SEM)
- Vascular biology
- Imaging tools: Tumor imaging in vivo; live tumor visualization ,microscopy
- Nanoparticles fabrication (PLGA, PEG)
- Rational drug design
- Drug encapsulation in nanoparticles and analysis of drug release profile (HPLC).
Educational and Professional History
Rabin Medical Center-Beilinson Campus, Israel present
Research Project Manager: supervised by Prof. Dov Weinberger, head of the Ophthalmology department.
- Developing new applications of surgical sealants for different eye diseases.
- Developing ferro-based nano vehicles for eye surgeries.
- Evaluating the feasibility of magnetic-remote control over ferro-based nano vehicles for eye surgeries.
- Evaluating the feasibility of a new medical device for IOP
UNC, Chapel Hill, NC, USA 2010-Early 2012
Post Doctoral Fellow: Supervised by Prof. Joseph DeSimone.
Research Subject- Study and evaluate Chemo-loaded NPs of different size and shape for cancer models.
- Nanoparticle fabrication, drug encapsulation and encapsulation analysis
- In vitro release studies of encapsulated drugs
- In vivo pharmacokinetics (PK) studies
- In vivo Imaging – Found a novel approach for tumor imaging using the PLGA-dye polymer
- An academic lab using a business platform with the appropriate Q-meetings and internal lab reports.
- Writing SOP for and conducted research under GMP conditions.
Weill Cornell Medical College, NYC, USA 2007-2010
Post Doctoral Fellow: Supervised by Dr. Meena Katdare
Research Subject- Study mutagens and carcinogens associated with mammary tumorgenesis pathways.
- Susan G. Kolmen for the cure “Scholar-In-Training Award” for the AAC Frontier in Cancer Prevention Research Conference (2008)
- Supervised a group of PhD students, surgery residents and pre-Med students
- Expert in Tumor cell biology and tissue culture
- Tumor-animal studies and drug administration
Tel-Aviv University, Tel-Aviv, Israel 2003-2007
PhD in Medical Science/ Cell Biology: Supervised by Dr. Gad Lavie
Department of Cell Biology, Sackler School of Medicine
PhD thesis: “The mechanism of inhibition of angiogenesis by Hypericin”
- Found the antiangiogenic properties of Hypericin. Hypericin was re-patented by HyBiopharma and enter phase I clinical trials for glioblastoma. HyBiopharma www.hybiopharma.com
- A research assistant for a project on Multiple Sclerosis (MS) in the Sheba Medica Center, Tel – Hashomer, Ramat Gan.
- First place awarder at the Sheba Medical Center Research day (2004)
- Travel fellowship by Michaelson Club Symposium for Eye Research (2007)
- Supervised and guided master students in their projects.
Tel-Aviv University, Tel-Aviv, Israel 2000-2002
M.Sc in Medical Science/ Cell Biology: Supervised by Dr. Lavie
Department of Cell Biology, Sackler School of Medicine.
- Graduated with honor
- Research assistant for a project on Multiple Sclerosis (MS) in the Sheba Medical Center, Tel – Hashomer, Ramat Gan.
- Volunteered as a tutor for students with learning difficulties.
Tel -Aviv University, Tel-Aviv, Israel 1998-2000
B.Sc in Life Science
- Volunteered as a tutor for students with learning difficulties.
Professional work experience
2000- 2007 – Sheba Medical Center- Tel Hashomer
Acquired knowledge while being a research assistant in a clinical trial for Multiple Sclerosis patients in the Sheba Medical Center (Israel). This experiment included producing T-cell vaccinations, characterizing them on their TCR vβ and gene profiles.
- In vitro; T cell receptor sequencing
Awards and Scholarships
2004 – First place awarde at the Sheba Medical Center Research day
2007 – Travel fellowship by Michaelson Club Symposium for Eye Research
2008 – Susan G. Kolmen for the cure “Scholar-In-Training Award” for the AACR Frontier in Cancer Prevention Research Conference
2004 – Tel Aviv University Cancer Research Center, Cefar Blum, Israel
2004 – Sheba Medical Center Research day
2005 – Michaelson Club Symposium for Eye Research, Belgium
2006 – Israeli Eye Research, Neve Ilan, Israel
2007 – Israeli Eye Research, Neve Ilan, Israel
2007 – Tel Aviv University Cancer Research Center, Israel
2007 – Michaelson Club Symposium for Eye Research, Baltimore USA.
2008 – AACR Frontiers in Cancer Prevention Research Conference, Washington DC,
2010 – 101 annual AACR meeting, Washington DC, USA
Barliya T., Mandel M., Livnat T., Weinberger D and Lavie G. “Degradation of HIF-1alpha Under Hypoxia Combined with Induction of Hsp90 Polyunbiquitination in Cancer Cells by Hypericin; a Unique Cancer Therapy”. PLoS ONE, 6(9) Sep 19, 2011.
Barliya T and Katdare M. “Preventive efficacy of curcumin on ENU-induced carcinogenic transformation of ApcMin/+ mammary epithelial (MinMG) cells established from ApcMin/+ mouse”. 101 Annual AACR meeting will be held in April 2010. Abstract.
Brooks R*., Barliya T.,*, Wynne N and Katdare M. “APC gene mutation and its role in breast carcinogenesis: Curcumin as a chemopreventive phytochemical”. J Am Coll Sur October 2009. Abstract. *co-authors
Barliya T., Gall-Troselj K., Crawford C. and Katdare M. “Curcumin downregulates IL-8 in DCIS breast cancer cells; correlation between tumorgenecity and inflammation”. 7th Annual AACR conference on Frontiers in Cancer Prevention Research, Nov. 2008; p38 (A34). Abstract
Mandel M, Achiron A, Tuller T, Barliya T, Rechavi G, Amariglio N, Loewenthal R, Lavie G. Clone clusters in autoreactive CD4 T-cell lines from probable multiple sclerosis patients form disease-characteristic signatures. Immunology 2009 Oct;128(2):287-300.
Lavie G, Barliya T et al. Competitive quenching”: a mechanism by which perihydroxylated perylenequinone photosensitizers can prevent adverse phototoxic damage caused by verteporfin during photodynamic therapy. Photochem Photobiol. 2007 Sep-Oct;83(5):1270-7.
Hazan Z, et al.Effective prevention of microbial biofilm formation on medical devices by low-energy surface acoustic waves. Antimicrob Agents Chemother. 2006 Dec;50(12):4144-52. Epub 2006 Aug 28.
Lavie G. et al. Anti-angiogenic activities of hypericin in vivo: potential for ophthalmologic applications. Angiogenesis. 2005;8(1):35-42.
Weinberger D. et al. Competitive quenching: a possible novel approach in protecting RPE cells from damage during PDT. Curr Eye Res. 2005;30(4): 269-277.
Achiron A.et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol. 2004;113(2):155-160.
Hebrew – native
English – fluent
French – Basic